Thermo Fisher Scientific delivers a perfect four-quarter earnings beat streak with 15% net margins and a Piotroski score of 8 out of 9, but a confirmed death cross with falling on-balance volume and an elevated put/call ratio of 1.70 create a cautious near-term technical backdrop.
Thesis pillars
- Perfect Beat Streak Margins→Stable
- Death Cross Falling Obv↑Improving
- Analyst Upside Asymmetry↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Thermo Fisher Scientific Inc (TMO) Stock Analysis
Breakout setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $659.48, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.8% away).
Thermo Fisher Scientific serves pharma, biotech, academic, and government customers through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Revenue comes from instruments, reagents,... Read more
Hold if already holding. Not a fresh buy at $659.48, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.8% away). Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Maintain position. Not compelling to add more. Score 5.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Thermo Fisher Scientific Inc
About Thermo Fisher Scientific Inc
Thermo Fisher Scientific operates through four business segments—Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services—serving pharmaceutical and biotech companies, hospitals, clinical diagnostic labs, universities, government agencies, and environmental and industrial markets worldwide. The company employed approximately 125,000 colleagues at December 31, 2025, with 59,000 in the Americas, 44,000 in EMEA, and 22,000 in the Asia-Pacific region, distributing products through an approximately 14,000-person direct sales force plus electronic commerce and third-party distributors.
Life Sciences Solutions provides biosciences, genetic sciences, and bioproduction products to pharmaceutical and biotech research markets. Analytical Instruments covers chromatography and mass spectrometry, chemical analysis, and electron microscopy tools sold into pharmaceutical, environmental, semiconductor, and academic markets. Specialty Diagnostics serves clinical laboratories with diagnostic kits, immunodiagnostics reagents, microbiology culture media, and transplant diagnostics. Laboratory Products and Biopharma Services—which includes the Patheon pharma services brand and the PPD clinical research brand—bundles consumables and equipment procurement with outsourced drug development, manufacturing, and Phase I through Phase IV clinical trials. Revenue is historically stronger in the fourth quarter due to capital spending patterns among industrial, pharmaceutical, and government customers. The company's raw-materials policy states that no single supplier is material, though certain components may be sourced from sole or limited suppliers for quality assurance or regulatory requirements.
Show full overview
Thermo Fisher carries active environmental remediation obligations at two named Superfund sites: the Fair Lawn Wellfields site in New Jersey, where the company entered a consent decree with the USEPA in 2020 to finance a groundwater treatment plant that was constructed in 2025 and transferred to the Borough of Fair Lawn in January 2026; and the former Davis Landfill site in Smithfield, Rhode Island, governed by a 2021 consent decree amendment calling for an interim remedy expected to commence in 2026. Accrued environmental liabilities totaled $86 million at December 31, 2025, and the company acknowledges that future regulatory changes could increase remediation scope and cost.
See also: Healthcare · Diagnostics & Research
From Thermo Fisher Scientific Inc's most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-09-18Recent Developments — Thermo Fisher Scientific Inc
Latest news
- NEWS Thermo Fisher shareholders reject say-on-pay at annual meeting - The Globe and Mail — The Globe and Mail negative
- NEWS Thermo Fisher Scientific Inc (TMO) Stock Up 4.9% and Still Under - GuruFocus — GuruFocus positive
- NEWS Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market - MarketWatch — MarketWatch positive
- NEWS Thermo Fisher Is Down 27% From Its Highs. The EPS Trough Looks Like It Is Already Behind the Company - TIKR.com — TIKR.com negative
- NEWS Thermo Fisher Scientific Inc Stock (TMO) Moved Up by 3.84% on Jun 24: What Investors Need To Know - TradingKey — TradingKey positive
Generated 2026-09-18T15:22:00Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $659.48, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.8% away). Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Maintain position. Not compelling to add more. Target $757.07 (+14.8%), stop $627.38 (−5.1%), A.R:R -1.2:1. Score 5.5/10, moderate confidence.
Take-profit target: $757.07 (-11.8% upside). Target $757.07 (+14.8%), stop $627.38 (−5.1%), A.R:R -1.2:1. Stop-loss: $627.38.
Analyst target reached - limited upside remaining; Near 52-week high (0.8% away); Expensive valuation.
Thermo Fisher Scientific Inc trades at a P/E of 34.9 (forward 23.9). TrendMatrix value score: 4.0/10. Verdict: Hold.
36 analysts cover TMO with a consensus score of 4.1/5. Average price target: $645.
What does Thermo Fisher Scientific Inc do?Thermo Fisher Scientific serves pharma, biotech, academic, and government customers through four segments: Life...
Thermo Fisher Scientific serves pharma, biotech, academic, and government customers through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Revenue comes from instruments, reagents, consumables, and outsourced drug manufacturing (Patheon/PPD), sold through ~14,000 direct sales staff plus distributors. The company employs approximately 125,000 globally.